Drug
YK012
YK012 is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(80%)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting4
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
not_yet_recruiting120%
recruiting480%
Recent Activity
4 active trials
Showing 5 of 5
recruitingphase_1
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301
recruitingphase_1
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835
recruitingphase_1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689
not_yet_recruitingphase_1
A Phase I Study of YK012 in Primary Membranous Nephropathy
NCT07234474
recruitingphase_1
Study of YK012 in Primary Membranous Nephropathy
NCT06982729
Clinical Trials (5)
Showing 5 of 5 trials
NCT06580301Phase 1
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT07010835Phase 1
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT06565689Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT07234474Phase 1
A Phase I Study of YK012 in Primary Membranous Nephropathy
NCT06982729Phase 1
Study of YK012 in Primary Membranous Nephropathy
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5